Epstein Secrets

5%: -7.8% QCH-eligible: No Amount outstanding: $3.7125 bn Assumes convert held to matunty; oil coupons included EFTA00821594 Source: Bloomberg Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, Sth Floor, New York, NY 10036 Phone:

pital to drive shareholder return. Next catalyst will be 2Q earnings/2/116 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where s

denbal and/or PlOPfletiq and subsect to important terms and corn:Event available at If you are not the molded rocosent. please delete this message. Amanda Ens Director The power of global connections" 6,,y_klimage031.png@OlD184D 2.3462f410 This message, and any attachments, is for the intended reel len

pital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where sca

ough the AGN A mandatory convert preferred at=a 6.3% current yield to March 2018. Let me know if you hav= time for a call; I'm at Thanks, Amanda Amanda Ens Director </=pan> Bank of America Merril= Lynch Merrill Lynch, Pierce,=Fenner & Smith Incorporated One Bryant Park, 5th F=oor, New York, NY 10036

l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where

ccount is not open yet so we likely need to wait until next week. Sorry for the inconvenience. Please let me know what you prefer. Thanks, Amanda Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10036 Phone:

pital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where

Amanda Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10036 <mailto

apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where

nkofamerica.com/emaildisclaimer <http://www.bankofamerica.com/emaildisclaimer> . If you are not the intended recipient, please delete this message. Amanda Ens Director Bank of America Merrill Lynch 15 EFTA_R1_01555903 EFTA02454275 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5

apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where

nkofamerica.com/emaildisclaimer <http://www.bankofamerica.com/emaildisclaimer> . If you are not the intended recipient, please delete this message. Amanda Ens Director Bank of America Merrill Lynch 16 EFTA_R1_001 07695 EFTA01785514 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park,

apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where